Korro Bio, Inc. (KRRO)
NASDAQ: KRRO · Real-Time Price · USD
12.80
-0.04 (-0.31%)
At close: Apr 28, 2026, 4:00 PM EDT
13.05
+0.25 (1.95%)
After-hours: Apr 28, 2026, 4:47 PM EDT

Korro Bio Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
6.392.27---
Revenue Growth (YoY)
181.46%----
Cost of Revenue
55.1352.3148--
Gross Profit
-48.74-50.04-48--
Selling, General & Admin
38.641.8736.5421.3914.06
Research & Development
---37.6121.43
Operating Expenses
38.641.8736.545935.49
Operating Income
-87.34-91.91-84.53-59-35.49
Other Non Operating Income (Expenses)
5.238.473.390.9813.54
EBT Excluding Unusual Items
-82.11-83.44-81.15-58.02-21.96
Merger & Restructuring Charges
-3.63----
Asset Writedown
-30.89----
Pretax Income
-116.62-83.44-81.15-58.02-21.96
Income Tax Expense
0.640.140.030.010
Net Income
-117.26-83.58-81.17-58.03-21.96
Net Income to Common
-117.26-83.58-81.17-58.03-21.96
Shares Outstanding (Basic)
99204
Shares Outstanding (Diluted)
99204
Shares Change (YoY)
5.32%483.30%499.32%-94.26%-
EPS (Basic)
-12.48-9.37-53.08-227.42-4.94
EPS (Diluted)
-12.48-9.37-53.08-227.42-4.94
Free Cash Flow
-79.08-77.98-75.12-58.86-36.54
Free Cash Flow Per Share
-8.42-8.74-49.12-230.65-8.22
Operating Margin
-1366.43%-4047.12%---
Profit Margin
-1834.48%-3680.36%---
Free Cash Flow Margin
-1237.16%-3433.55%---
EBITDA
-83.06-88.35-80.9-56.49-33.9
D&A For EBITDA
4.283.573.632.511.6
EBIT
-87.34-91.91-84.53-59-35.49
Source: S&P Capital IQ. Standard template. Financial Sources.